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Abstract: The brain is very actively involved in immune-inflammatory processes, and the 
response to several trigger factors such as trauma, hemorrhage, or ischemia causes the release 
of active inflammatory substances such as cytokines, which are the basis of second-level dam-
age. During brain ischemia and after brain trauma, the intrinsic inflammatory mechanisms of 
the brain, as well as those of the blood, are mediated by leukocytes that communicate with each 
other through cytokines. A neuroinflammatory cascade has been reported to be activated after a 
traumatic brain injury (TBI) and this cascade is due to the release of pro- and anti-inflammatory 
cytokines and chemokines. Microglia are the first sources of this inflammatory cascade in the 
brain setting. Also in an ischemic stroke setting, an important mediator of this inflammatory 
reaction is tumor necrosis factor (TNF)-α, which seems to be involved in every phase of 
stroke-related neuronal damage such as inflammatory and prothrombotic events. TNF-α has 
been shown to have an important role within the central nervous system; its properties include 
activation of microglia and astrocytes, influence on blood–brain barrier permeability, and 
influences on glutamatergic transmission and synaptic plasticity. TNF-α increases the amino-
3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor density on the cell surface and 
simultaneously decreases expression of γ-aminobutyric acid receptor cells, and these effects are 
related to a direct neurotoxic effect. Several endogenous mechanisms regulate TNF-α activity 
during inflammatory responses. Endogenous inhibitors of TNF include prostaglandins, cyclic 
adenosine monophosphate, and glucocorticoids. Etanercept, a biologic TNF antagonist, has 
a reported effect of decreasing microglia activation in experimental models, and it has been 
used therapeutically in animal models of ischemic and traumatic neuronal damage. In some 
studies using animal models, researchers have reported a limitation of TBI-induced cerebral 
ischemia due to etanercept action, amelioration of brain contusion signs, as well as motor and 
cognitive dysfunction. On this basis, it appears that etanercept may improve outcomes of TBI 
by penetrating into the cerebrospinal fluid in rats, although further studies in humans are needed 
to confirm these interesting and suggestive experimental findings.
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Introduction
Traumatic brain injury (TBI) and ischemic stroke are pathological events known to be 
significantly associated with a high rate of morbidity and mortality. These complex 
disorders are also characterized by two levels of damage that encompass primary and 
secondary injury pathological events.1
It is possible to schematize primary injury in these two clinical settings as follows:
1. In TBI: damage due to mechanical factors synchronous with the time of trauma 
to neurons, axons, glia, and blood vessels, which can be considered a result of 
shearing, tearing, or stretching.
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2. In ischemic stroke: ischemic damage that occurs after 
a variable time interval following the initial ischemic 
event. Ischemic damage is also due to a wide range 
of delayed neurochemical or metabolic alterations at 
a cellular level.
Secondary injury mechanisms in both these clinical 
conditions include processes such as alteration of ionic 
homeostasis,2 increase of neurotransmitter levels (eg, gluta-
mate-linked excitotoxicity mechanisms),3 neuronal apoptosis,4 
lipid degradation,5 and immune-inflammatory activation.6 
These neurochemical events involve inflammatory mediators, 
such as prostaglandins, oxidative metabolites, and inflamma-
tory cytokines. This inflammatory activation causes a complex 
cascade of molecular events such as lipid peroxidation, blood–
brain barrier (BBB) disruption, and cerebral edema.
Cerebral ischemia and TBI induces a cascade of inflam-
matory reactions that encompass genomic events as well as 
molecular and cellular alterations that occur in the central 
nervous system (CNS). In this series of inflammatory altera-
tions, cytokines represent a central mediator of a stroke-
linked immune-inflammatory cascade that leads to neuronal 
damage, inflammatory brain reactions linked to brain infarct 
size progression, and complex pathological events following 
a brain trauma.7
Recently, it became clear that inflammatory mediators 
such as cytokine release mediated by T cells and mononuclear/
macrophage cells regulate many functions of some CNS cells 
such as macroglial and microglial cells. In particular, glial 
cells when activated can produce immunoregulatory factors 
that influence other cellular subsets such as mononuclear 
cells and glial cells.2
Cytokines such as tumor necrosis factor (TNF)-α, 
interferons, growth factors, colony-stimulating factors, and 
chemokines are pleiotropic proteins that express a wide range 
of processes, either physiological or pathological.
TNF-α plays an important role during cerebral ischemia: 
it exerts a chemotactic action toward leukocytes and induces 
the production of adhesion molecules in other cellular sub-
types, such as several leukocyte subsets, endothelial cells, 
and other target cells, thus increasing inflammation events in 
the cerebral setting.8 Furthermore, TNF-α has a clear effect 
on enhancing thrombogenesis by increasing plasminogen-
activating inhibitor-1 tissue factor and platelet-activating 
factor levels, and by inhibition of tissue plasminogen activa-
tor activity.8
On this basis, it is possible to suggest that, far from being 
an immunological sanctuary, brain is very actively involved 
in immune-inflammatory processes as a result of several 
trigger factors such as trauma and ischemia, and that these 
injuries to the brain are expressed by the release of media-
tors such as cytokines with their leading role in causing the 
so-called secondary neuronal damage.9
After focal brain ischemia, microglial cells gain an 
activated phenotype and they rush into the penumbra area 
and exacerbate and maintain neuronal injury at this site by 
several pathways of pathogenic events and mediators, such 
as poly(ADPribose) polymerase-1 activation and  multiple 
matrix metalloproteinase (MMP) activation.4
In particular, MMP can influence the integrity of the BBB 
through damage of the endothelial function of this barrier, 
thus impairing the whole functional integrity of the so-called 
neurovascular unit. These pathological events may open a 
door for the entry of peripheral inflammatory cells into the 
brain, thus exposing neuronal cells to the attack of peripheral 
immune-competent cells.
After cerebral ischemia, it is possible to observe the 
induction of a series of inflammatory events such as infil-
tration of neutrophils and monocytes; activation of resi-
dent inflammatory cells such as microglia, astrocytes, and 
endothelial cells;8 and involvement of T cells and natural 
killer cells. All these inflammatory events are also initiated 
after a brain trauma by TNF-α, which is a pleiotropic pro-
tein involved in the regulation of numerous physiological 
and pathological processes, such as inflammation, cancer, 
autoimmunity, and infection.
Neuroinflammation after brain 
trauma
The immune-inflammatory activation after TBI is mediated 
by inflammatory mechanisms. Among the resident CNS cells, 
microglia represent a probable primary source of these inflam-
matory mediators in the CNS.2 Genetic studies in experimen-
tal models of TBI have shown that inflammatory genes are 
upregulated in the acute phase both after TBI and stroke.2–4
Additional studies analyzed genes of microglia inflam-
matory activation and their temporal-spatial localization after 
TBI, showing that chosen markers of microglial activation 
such as CD68, MHCII, or stress responses such as p22phox, 
heme oxygenase, or a gene related to chemokine activation 
such as CXCL10, CXCL6, are highly activated at a transcrip-
tional level after TBI.5,6
TNF-α and other cytokines such as interleukin (IL)-1β 
and IL-6 have pleiotropic actions in the brain; for example, 
they regulate and control both systemic host responses 
to disease and local alterations on vessels, neurons, and 
endothelial cells caused by CNS inflammation.8,9
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TNF-α, IL-1, and IL-6 are the main cytokines that have 
been reported as expressed by cultured brain cells in relation 
to various stimuli (Table 1). Astrocytes produce TNF-α in 
response to various stimuli such as lipopolysaccharide (LPS) 
and interferon-γ.10 Cultured cells of astrocytes also express 
high levels of other cytokines such as IL-6, IL-8, and granu-
locyte colony stimulating factor, in response to stimulation 
by IL-l or TNF-α.11
Activated microglia regulate astrocyte proliferation, 
and this cell regulation is also expressed by means of the 
production of TNF-α.12 A complex cytokine network creates 
communication among stimulated brain cells. These cell 
relationships mediated by immune-inflammatory media-
tors represent the basis of an influence of each cell on the 
functional status of other inflammatory cells involved in this 
inflammatory network in the CNS setting.13
In this way, TNF-α achieves chemotaxis control action 
effects as a result of increased production of other chemok-
ines. In addition, TNF-α may regulate other proteins called 
adhesion molecules, such as E-selectin, intercellular adhesion 
molecule (ICAM), vascular cell adhesion molecule (VCAM), 
and a monocyte adhesion protein.14,15
Table 1 Studies on etanercept in experimental models and major clinical trials of selective TNF inhibitors in the treatment of brain 
injury from stroke and trauma
Study Study design Results
wang et al82 The authors generated hybridomas that produced 
antibodies specific for p75TNFR, by inoculating 
BALB/c mice with antigenic peptides derived from 
mouse p75TNFR (critical to the binding of TNF-α 
and p75TNFR)
Seven mAbs against p75TNFR were generated mAb 
D8F2 enhanced the cytotoxicity of TNF-α on L929 cells
In a TBI model, D8F2 inhibited the levels of inflammatory 
factors and downregulated RNA transcription of these 
factors by suppressing the activation of p38 mitogen-
activated protein kinase and NF-κB
Belarbi et al83 The authors evaluated the therapeutic potential 
of a novel analog of thalidomide DT, an agent 
with anti-TNF-α activity, in a model of chronic 
neuroinflammation. LPS or artificial cerebrospinal 
fluid was infused into the fourth ventricle of 
3-month-old rats for 28 days. Starting on day 29, 
animals received daily intraperitoneal injections of 
DT (56 mg/kg/day) or vehicle for 14 days
Chronic LPS infusion was characterized by increased 
gene expression of the proinflammatory cytokines 
TNF-α and iL-1β in the hippocampus
Treatment with DT normalized TNF-α levels back to 
control levels but not iL-1β
Treatment with DT attenuated the expression of TLR2, 
TLR4, iRAK1 and Hmgb1, all genes involved in the 
TLR-mediated signaling pathway associated with classical 
microglia activation
Sun et al84 The authors investigated the effect of an NF-κB 
inhibitor SN50 on cell death and behavioral deficits 
in a mouse TBi model
Pretreatment with SN50 remarkably attenuated
TBi-induced cell death (detected by Pi labeling),
cumulative loss of cells, and motor and cognitive 
dysfunction 
Chio et al78 Anesthetized rats, after the onset of TBi, were 
divided into two major groups and given the vehicle 
solution (1 mL/kg of body weight) or etanercept 
(5 mg/kg of body weight) intraperitoneally once per 
12 hours for 3 consecutive days
Attenuation of TBi-induced cerebral ischemia markers 
(increased cellular levels of glutamate and lactate-to-
pyruvate ratio), damage (eg, increased cellular levels of 
glycerol)
Amelioration of contusion, and motor and cognitive 
function deficits
Tobinick63 Three consecutive patients with stable and 
persistent chronic neurological deficit after ischemic 
stroke that were treated off-label with perispinal 
etanercept (13, 35, and 36 months following stroke)
improvement in hemiparesis, gait, hand function, hemi-
sensory deficits, spatial perception, speech, cognition, 
and behavior 
Chio et al81 A rat model of TBi treated with etanercept 
immediately after TBi
Etanercept therapy significantly attenuated TBI-induced 
cerebral ischemia, neurological motor deficits, and 
increased numbers of microglia-TNF-α double positive 
cells and increased TNF-α levels in the injured brain
Tobinick et al91 629 consecutive patients, 617 patients following 
stroke, and 12 patients following TBi were 
evaluated to analyze the clinical response following 
perispinal administration of etanercept
Significant improvements in motor impairment, spasticity, 
sensory impairment, cognition, psychological/behavioral 
function, aphasia
Abbreviations: DT, 3,6′-dithiothalidomide; Hmgb 1, high mobility group box 1; iL, interleukin; iRAK1, iL-1 receptor-associated kinase 1; LPS, lipopolysaccharide; mAb, 
monoclonal antibody; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; Pi, phosphatidylinositol labeling, SN50, inhibitor SN50; TBi, traumatic brain injury; 
TLR, toll-like receptors; TNF, tumor necrosis factor; TNFR, TNF-α receptor.
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A higher degree of expression of adhesion molecules 
in astrocytes enhances a migration process of inflammatory 
cells, and it represents one of the possible pathogenic bases of 
inflammatory-mediated ischemic neuronal damage. ICAM-1 
and VCAM-1 have been reported as highly expressed in cultured 
microglial cells after treatment with TNF-α.16 A high degree 
of expression of ICAM-1, VCAM-1, and E-selectin has also 
been shown in cultured endothelial cells from brain vessels after 
exposure to inflammatory stimuli such as TNF-α17 (Figure 1).
Neuroinflammation after brain 
ischemia
An induction of messenger RNAs (mRNAs) of several 
cytokines such as IL-1β, IL-18, IL-6, and TNF-α after 
ischemic damage has been reported.18 High levels of TNF-α 
mRNA has been shown 1 hour after middle cerebral artery 
occlusion (MCAO), with a peak level at 12 hours, and 
persistently high levels for 5 days after experimental brain 
ischemia caused by arterial occlusion.19,20
A good example of neuroinflammation-mediated 
neuronal damage has been reported in heat stroke. In a 
study by Lin et al heat stroke, a reproducible model of brain 
injury, has been caused in rats exposed to a temperature 
of 42°C.22 This study reported that extracellular levels of 
some neurotransmitters and mediators such as dopamine, 
serotonin, or norepinephrine were upregulated in some brain 
areas such as the hypothalamus and corpus striatum in the 
course of the heat-stroke-induced cerebral ischemia and 
neuronal damage. The same authors showed high serum and 
brain levels of TNF-α induced by heat stroke and cerebral 
ischemic damage. They also demonstrated that depletion 
of brain dopamine or serotonin after an intracerebral injec-
tion of 6-hydroxydopamine or 5,7-dihydroxytryptamine 
ameliorated heat-stroke-induced cerebral ischemia. These 
findings indicate how increased brain levels of either dop-
amine or serotonin may represent important mediators for 
heat-stroke-induced cerebral ischemia and neuronal damage 
in experimental animal models.
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Figure 1 Common inflammatory pathways involved in neuronal damage after TBI and ischemic stroke.
Abbreviations: Alpha-Syn, alpha-synuclein; ATP, adenosine triphosphate; BBB, blood –brain barrier; BDNF, brain-derived neurotrophic factor; CSF-1, colony-stimulating 
factor 1; GM-CSF, granulocyte-macrophage colony-stimulating factor; HAP1, Huntingtin-associated protein 1; HD, Huntington’s disease; iFN, interferon; iL, interleukin; MMP, 
matrix metalloproteinase; mHtt, mutant Huntingtin protein; NGF, nerve growth factor; PD, Parkinson’s disease; ROS, reactive oxygen species; TBi, traumatic brain injury; 
TGF, tumor growth factor; Th, T-helper; TK-r, receptor tyrosine kinases; TNF, tumor necrosis factor; TRkB, neurotrophic tyrosine kinase receptor, type 2; veGF, vascular 
endothelial growth factor.
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Nevertheless, it is not easy to find a clear answer to the 
question of a possible source of inflammatory cytokines 
involved in ischemia-related neuronal damage. To answer 
this difficult question, some researchers such as Tarkowski 
et al23 evaluated serum and cerebrospinal fluid (CSF) levels 
of IL-lβ and IL-6 in patients with ischemic stroke. These 
authors showed higher levels of these cytokines in the CSF 
than in the serum. These findings suggest the possible exis-
tence of direct intracerebral production of these inflammatory 
cytokines strictly involved in the pathogenesis of ischemic 
neuronal damage.
Other authors such as Mathiesen et al reported a nonpar-
allel increase of levels of IL-6 in the CSF and in the serum 
in subjects with subarachnoid hemorrhage.24 They also 
reported that increased levels of cytokines such as TNF-α 
were higher at day 6 and that these higher levels were more 
likely to be linked to the development of delayed ischemic 
neurological deficits.
Common pathways after TBI 
and ischemia
Higher degree of inflammatory activation in terms of TNF-α 
plasma levels has been observed in experimental models 
of brain ischemia as well as in patients with acute stroke23 
and in patients with large cerebral infarct volume and poor 
stroke outcome.24
A neuroinflammatory cascade has also been described 
after a head trauma. A first event of this inflammatory cas-
cade is microglia activation (MA) after either a traumatic or 
ischemic injury. After microglia involvement, it is possible 
to observe an increase in inflammatory cytokines such as 
IL-1β and TNF-α in both humans and rodents.25–28
TNF-α enhances the toxic effects of IL-1β in a syner-
gistic way, thus both these inflammatory cytokines seem to 
regulate and induce neuroinflammation and brain damage 
after TBI29 and ischemic stroke.27,28 Nevertheless, the role of 
TNF-α in TBI-related neuronal damage remains less clear, 
with different findings in relation to studies conducted by 
evaluating acute and delayed stages of neuronal damage 
after TBI.30
Three different compounds have been reported as neu-
roprotective agents by means of a blocking action toward 
TNF-α. These substances are dexanabinol (HU-211), the 
TNF-binding protein, and pentoxifylline. Some researchers 
have reported that these substances are effective in offer-
ing a significant amelioration in neurological outcomes, 
probably also acting on BBB disruption and brain edema 
pathogenesis.31,32
It is possible to block inflammatory effects of cytokines 
and chemokines by several methods, including neutralizing 
antibodies, soluble cytokine/chemokine receptors, inhibitors 
of cytokine/chemokine synthesis, and anti-inflammatory 
cytokines.
Role of TNF-α in brain damage 
after ischemia
TNF-α levels progressively increase in ischemic brain dam-
age after a TBI.33 High levels of TNF-α are strictly linked 
to BBB disruption34 and neuronal cell death after TBI and 
ischemic damage. TNF-α has been reported as a mediator 
in the mechanism of neuronal death in experimental models 
of neuronal damage caused by oxygen-glucose deprivation 
(OGD model) in vitro and in animal models of ischemic 
brain damage by means of brain artery occlusion or ligation.35 
Some apoptotic pathways of neuron death showing peripheral 
aggregates have also been reported as linked to increased 
levels of TNF-α.36
A study37 explored the pathophysiological significance 
of brain TNF-α in the ischemic brain. The authors evalu-
ated the effects of lateral cerebroventricular administra-
tion of exogenous TNF-α and tested agents that block the 
effects of TNF-α on focal stroke by administering TNF-α 
(2.5 or 25 pmol) intracerebroventricularly to spontane-
ously hypertensive rats 24 hours before MCAO. Animals 
were examined 24 hours later for neurological deficits and 
ischemic hemisphere necrosis and swelling. A neutralizing 
anti-TNF-α monoclonal antibody (mAb) (monoclonal 
hamster anti-murine TNF-α) was also administered in some 
of experimental animals (mAb intracerebroventricularly 
30 minutes before exogenous TNF-α). They evaluated the 
direct neurotoxic effects of TNF-α in cultured rat cerebellar 
granule cells exposed to TNF-α by means of the evaluation 
of  neurotransmitter release, glutamate toxicity, and oxy-
gen radical toxicity, reporting that TNF-α increased after 
hemispheric infarct induced by MCAO. The toxic effects 
of TNF-α on brain, evaluated by means observation of 
swelling and neurological deficit after exogenous TNF-α, 
have been re ported as reversed by preinjection of 60 pmol 
mAb.37 Blocking endogenous TNF-α also significantly 
reduced focal ischemic brain injury and reduced infarct 
size compared with control. These experimental experi-
ences demonstrate that exogenous TNF-α exacerbates focal 
ischemic injury and that blocking endogenous TNF-α is 
neuroprotective. The specificity of the action(s) of TNF-α 
was demonstrated by antagonism of its effects with specific 
anti-TNF-α tools (ie, mAb and soluble TNF-α receptor 1 
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[sTNFR1]). TNF-α toxicity does not appear to be due to a 
direct effect on neurons or modulation of neuronal sensitivity 
to glutamate or oxygen radicals but apparently is mediated 
through nonneuronal cells. These data suggest that inhibiting 
TNF-α may represent a novel pharmacological strategy to 
treat ischemic stroke.
Some authors reported that pretreatment with TNF-α 
in BALB/C mice prior to an experimental stroke induced 
by MCAO is associated with a significantly lower exten-
sion of brain infarct size,38 and to explain these findings 
the authors suggested a neuroprotective mechanism of 
ischemic preconditioning. Some CNS resident cells such as 
macrophages, astrocytes, and microglia synthesize TNF-α, 
which has inflammatory action in the CNS during the acute 
phase, but also immunosuppressive effects during the chronic 
phase.39
Several reports show that TNF-α is involved in several 
crucial pathways within the CNS (Figure 2).40–47 These 
pathways induce the activation of microglia and astrocytes, 
act on BBB integrity, enhance  glutamatergic transmission, 
and regulate synaptic plasticity. Furthermore, a mechanism 
of scaling of excitatory synapses has been reported as linked 
to TNF-α promotion of amino-3-hydroxy-5-methyl-4-isox-
azolepropionic acid (AMPA) receptors and downregulation 
of γ-aminobutyric acid (GABA) receptors on the cell surface. 
These findings could suggest a possible role of TNF-α in the 
regulation of synaptic transmission at excitatory synapses, 
thus enhancing excitatory synaptic transmission and lowering 
inhibitory synaptic transmission.48–51
Some studies report that treatment with TNF-α recep-
tor (TNFR) or anti-TNF-α antibody is able to reduce 
tetrodotoxin-induced promotion in the expression of AMPA 
receptors and increase spontaneous miniature excitatory 
synaptic current (mEPSC) amplitude, whereas they have 
been reported to decrease miniature inhibitory synaptic cur-
rent amplitude.48,49
These mechanisms of regulation of synaptic scaling have 
also been demonstrated in some experimental cell models 
such as hippocampus cultures in TNF-α-deficient mice 
in which the authors did not report an increased mEPSC 
amplitude compared to wild-type cultures, thus underlying 
a TNF-α dependence on higher mEPSC amplitudes.48,49
Some research studies also reported how TNF-α is 
involved in the stimulation of tissue factor and adhesion 
molecule expression and in the induction of enhanced activity 
or higher levels of nitric oxide, factor VIII/von Willebrand 
factor, and platelet activating factor. In a procoagulant set-
ting, TNF-α is also linked to endothelin, suppression of the 
thrombomodulin-protein C-protein S system, reduction of 
tissue plasminogen activator, and stimulation of release of 
plasminogen activator inhibitor-1. It also enhances MMP 
levels, thus actively acting on vascular permeability, which 
increases in response to TNF-α action. TNF-α can also 
induce reactive oxygen species synthesis on endothelial cells 
by means of an upregulation of some regulatory enzymes 
such as xanthine oxidase, cyclooxygenase, and nicotinamide 
adenine dinucleotide phosphate hydrogen oxidase, which 
are key enzymes in reactive oxygen species production 
pathways.50,51
All these cumulative effects increase the likelihood of 
local, inflammatory, and thrombotic micro events, thus 
inducing humeral and molecular backgrounds that predispose 
mechanisms of stroke initiation and induce the progression of 
ischemic neuronal damage after an ischemic stroke. TNF-α 
has an important role in the pathogenesis of atherosclerotic 
stroke through its role in promoting atherosclerotic 
plaque development and mechanisms that make these 
plaques unstable.52 TNF-α has a role in local endothelial 
prothrombotic and proinflammatory micro events.
Chemotaxis of lymphocytes and monocytes to athero-
sclerotic plaque has also been reported as directly stimulated 
by TNF-α, which enhances endothelial-cell adhesion mol-
ecule expression and elaboration of chemokines involved 
in chemotaxis mechanisms. TNF-α is involved in the accu-
mulation of lipid-laden foam cells and smooth-muscle-cell 
proliferation, which are all key events in atherosclerosis 
development. One study on cultured macrophages from 
carotid plaques have reported the atherogenic properties 
of TNF-α on cultured macrophages from carotid plaques. 
These studies reported an increased degree of TNF-α, both 
serum and cell-linked, compared to the levels expressed by 
analyzing circulating control monocytes.51
The important role of TNF-α in ischemic stroke promo-
tion has been demonstrated in reports of TNF-α activation 
in experimental brain ischemia models at both the mRNA 
and protein levels.53 Existing data on the time course of this 
cytokine after an acute ischemic stroke offer important infor-
mation about the role of TNF-α in acute ischemic stroke in 
humans. A very important study by Sairanen et al evaluated 
the brain tissue distribution by analyzing its temporal kinetics 
and showed TNF-α brain tissue distribution pathways after 
an ischemic stroke (Figure 3).54 The study showed a typical 
neuronal TNF-α immunoreactivity pattern of cytoplasmic 
punctate staining with a swollen filament-like structure on 
the first day after ischemic stroke. On the second day, TNF-α 
immunoreactivity was reported only in a small number of 
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neurons of the infarct core and in contralateral locations in 
dead subjects. Inflammatory cells showing TNF-α immu-
noreactivity were also observed in the infarct core on the 
second day, whereas a bilateral pattern of neuronal TNF-α 
immunoreactivity was reported after the second day.
On the third day, contralateral neuronal immunoreactiv-
ity decreased, whereas neuronal TNF-α immunoreactivity 
was demonstrable at 5.4 days in the infarct core and peri-
infarct areas. A second wave of TNF-α immunoreactivity 
was also observed on astrocytes on the third day after an 
acute ischemic stroke. After 2 weeks, TNF-α immunore-
activity was shown, with inflammatory cells infiltrating 
the affected hemisphere in a chemotactic manner and 
resident astrocytes of controlateral brain areas only in a 
small amount.
The experimental findings of Sairanen et al54 offered 
a confirmation of the role of TNF-α production as a key 
element of neuronal damage after an acute ischemic 
stroke in humans. The long duration of kinetic distri-
bution of TNF-α response observed in humans, with 
a peak between the second and the third day after an 
acute ischemic stroke and maintaining a high degree of 
TNF-α immunoreactivity at 2 weeks after stroke, fosters 
speculation about a possible therapeutic intervention in 
the immune-inflammatory background of the acute phase 
of ischemic stroke demonstrated by the progressive brain 
immunoreactivity of TNF-α.
Other researchers have suggested the possibility of a dual 
role of TNF-α in experimental models of ischemic stroke, 
such as a murine model in which the authors used LPS to 
induce  LPS tolerance in the postischemia phase and in cell 
cultures with neuronal cells.55 These authors reported how 
LPS preconditioning resulted in a significant increase in 
circulating levels of TNF-α before experimental ischemic 
stroke induction by means of MCAO in mice; they also 
reported that the presence of TNF-α is necessary to induce 
a neuroprotective effect after experimental brain ischemia, 
and this issue has been supported by findings concerning the 
absence of neuroprotective effect after LPS injury in mice 
lacking TNF-α.55
Furthermore, these authors observed in LPS-preconditioned 
experimental mice a lowering of TNF-α, thus resulting in 
a subsequent neuronal modulation of a series of signaling 
molecules related to TNF-α such as TNFR1 and TNFR-
associated death domain. Particularly interesting, it also 
appears that sTNFR1 levels increased after a stroke in LPS-
preconditioned experimental mice, and this finding could 
explain a possible neutralizing effect toward TNF-α, thus 
ameliorating and lowering neuronal damage mechanisms 
mediated by TNF-α.
Role of TNF-α in brain damage 
after brain trauma
The role of TNF-α has also been evaluated in a more strictly 
traumatic setting. Some authors further examined the role 
of TNF-α in the acute pathophysiology of TBI.56 They 
analyzed TNF-α kinetics in terms of its expression, local-
ization, and regulation in an experimental mouse model of 
head trauma. These authors observed higher TNF-α levels 
in brain cortex after TBI at 1 hour and 4 hours but not at 
12 hours, 24 hours, or 72 hours. In early phases (between 
1 hour and 4 hours after TBI), significantly higher levels 
of TNF-α have been reported as immunocytochemically 
detectable in neurons of the injured cerebral cortex, whereas 
positive immunochemistry staining for TNF-α has been 
reported in a small subset of astrocytes, ventricular cells, 
and microvessels, although this positive immunochemistry 
was not evaluated as TBI-dependent. Furthermore, these 
authors did not observe TNF-α expression in macrophages 
resident in the hemorrhagic zone along the external capsule 
and corpus callosum.
In the same research, intracerebroventricular administra-
tion of a selective TNF-α antagonist-sTNF-α receptor fusion 
protein in the early phase after TBI (at 15 minutes and at 1 
hour after TBI) significantly ameliorated functional outcome 
in experimental mice, whereas intravenous administration 
of the same compound at the same time intervals did not 
result in the same findings. These results underline the fact 
that increased TBI-related TNF-α is responsible for many 
facets of subsequent neurological impairment.
Selective TNF inhibitors in the 
treatment of brain injury 
from ischemic stroke
Several possible mechanisms may control TNF-α activity 
during inflammatory activation. Endogenous inhibitors of 
TNF-α, such as prostaglandins and cyclic adenosine mono-
phosphate, which inhibit TNF-α production, and glucocor-
ticoids that upregulate in the presence of high TNF-α levels 
by means of activation of the hypothalamus pituitary adrenal 
axis, inhibit TNF-α production.57,58
Some authors55 evaluated neurons and microglial cells 
after treatment with IL-1β or IL-1 receptor agonist (ra) for 
10 days in hippocampus slice cultures (OHSCs) from rats 
after an excitotoxic TBI by means of N-methyl-D-aspartate 
(NMDA). These researchers analyzed OHSCs by means of 
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bright-field microscopy after hematoxylin staining and con-
focal laser scanning  microscopy, after labeling of damaged 
neurons with propidium iodide and fluorescent staining of 
microglial cells. They reported that treatment with IL-1β 
in unlesioned OHSCs did not induce neuronal damage 
but induced an increase in the number of microglial cells, 
whereas excitotoxic NMDA-mediated lesions resulted in 
a higher density of microglial cells. Treatment of NMDA-
lesioned OHSCs with IL-1β increased neuronal cell death 
and upregulated microglia cell density. In NMDA-lesioned 
culture, treatment with IL-1ra resulted in a significant ame-
lioration of neuronal damage and reduced the number of 
microglial cells, whereas treatment with IL-1ra in unlesioned 
OHSCs has been reported as not inducing significant changes 
in the evaluated cell population.
On the basis of these facts, it is possible to suggest that: 
1) IL-1β has a direct role in the pathogenesis of TBI-induced 
neuronal damage in the CNS setting; 2) IL-1β is responsible 
for microglia cell subset activation whereas it is not directly 
neurotoxic; 3) IL-1β is able to regulate excitotoxic neuronal 
damage and microglia upregulation; and 4) IL-1ra treatment 
inhibits neuronal cell death and downregulates microglia cell 
number after TBI by means of an excitotoxic damage.
Several anti-inflammatory mediators negatively regulate 
TNF-α action, such as IL-10, IL-13, and IL-4.51–53 Further-
more, other proteins are able to regulate TNF-α production 
such as the TNF-α converting enzyme (TACE) by cleaving the 
transmembrane form of TNF-α and generating its soluble form 
(sTNF-α). This enzyme can also modulate TNF receptors, 
generating sTNFRs able to bind circulatory sTNF.54–56,59
The vagus nerve has also been shown to inhibit TNF-α 
production by means of a cholinergic activation of muscarinic 
receptors.57 A series of proteins act as TNF-α inhibitors and 
have been called biologics, and their use has been used in the 
treatment of inflammatory and autoimmune disorders includ-
ing rheumatoid and juvenile arthritis, ankylosing spondylitis, 
and Crohn’s disease. Among this class of drugs, infliximab, 
etanercept, and adalimumab act by binding soluble trans-
membrane form of TNF, thus inhibiting their interaction with 
TNF-α receptors. Infliximab, a chimeric bivalent Immuno-
globulin G1 mAb with a human constant region and amurine 
variable regions; adalimumab, a bivalent mouse Immuno-
globulin G1 mAb; and etanercept, a fusion protein of human 
IgG fused to a dimer of the extracellular regions of TNFR2, 
have been reported as active TNF-α inhibitor drugs.
Emerging evidence suggests that retrieved penumbra 
may be the site of ongoing inflammatory pathology, which 
includes extensive MA. This is a possible action area for 
TNF-α-blocking drugs. Etanercept has been reported to 
reduce MA in animal stroke models, and it has been reported 
as effective in reducing ischemic neuronal damage in murine 
models of brain ischemia and subsequent neuronal injury. 
Perispinal administration is a possible way to administer 
etanercept, and it has shown that perispinal administration 
is effective in Alzheimer’s disease,58,60,61 owing to the fact 
that this method of administration makes brain delivery of 
etanercept easier.
On this basis, a recent study evaluated the initial clinical 
response to perispinal etanercept in a first chronic stroke 
cohort.62 Researchers evaluated three patients with perma-
nent postischemic neurological deficits with hemiparesis, 
in addition to other stroke deficits due to previous middle 
cerebral artery, brainstem (medulla), and left middle cerebral 
artery infarcts. These patients were treated with perispinal 
etanercept at 13 months, 35 months, and 36 months following 
acute brain ischemia, and the authors observed a significant 
amelioration following perispinal etanercept administration 
with clinical response in 10 minutes. Clinical improvement 
has been observed as a significant amelioration of motor 
deficit (hemiparesis), gait disturbances, sensory deficits, 
spatial perception, speech functions, cognitive performance, 
and behavioral disturbances. The authors reported further 
clinical improvement with a second perispinal etanercept 
dose 20 days after the first dose. These findings suggest that 
stroke may result in chronic TNF-mediated pathophysiology, 
which may be potentially suitable for therapeutic intervention 
even beyond an acute phase.
Several studies have indicated how TNF-α production 
is regulated at both transcriptional and translational levels.63 
Potentially effective classes of drugs include calphostin C, 
protein kinase C inhibitors of microbial origin,64 for example, 
which are able to block LPS-stimulated TNF-α production 
either from human monocytes in vitro65 or LPS and virus-
stimulated TNF-α increase in astrocytic cell lines.66
Another possible application of a TNF-α blocking strat-
egy has been offered by a blocking treatment against some 
key enzymes involved in TNF biosynthesis pathways such as 
p38 and other monoaminophosphate kinases. Soluble TNF-α 
is catalyzed by the membrane-bound Zn-metalloprotease, 
TACE, which has been cloned using a pro-TNF-α peptide 
cleavage assay.67
One study suggested a crucial role for TACE as the 
major physiological TNF-α processing enzyme, and this 
activity has been shown to be susceptible to a metallopro-
tease inhibitor that significantly reduces LPS-induced TNF 
release in cells.68
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TACE has been shown to have an important role in the 
CNS both in physiological and pathological conditions,69 and 
some authors have reported that, after a cerebral ischemia, it 
is possible to observe a significant upregulation of gelatinase 
MMP-2 and MMP-9 activities, as well as signs of neuronal 
damage at hippocampus sites.70 In these experiments, it has 
been reported that treatment with BB-94 before and soon 
after a transient global ischemia induces a significant reduc-
tion in signs of hippocampus neuronal damage, producing 
a significant lowering of hippocampus gelatinase activities. 
Furthermore, Yang et al have shown that the TACE/MMP-9 
inhibitor KB-R7785 significantly reduces brain damage.71 In 
this study, the administration of KB-R7785 was reported to 
induce a significant lowering of infarct volume after MCAO 
in mice. All these studies demonstrate how TNF-α produc-
tion is a target of therapeutic interventions owing to the fact 
that its production is regulated at both transcriptional and 
translational levels (Figure 4).72
Inflammation- and apoptosis-associated regulatory path-
ways are other possible therapeutic targets in TBI-related 
neuronal damage. On this basis, some researchers analyzed 
the therapeutic strategy of blocking the mitogen-activated 
protein kinase (MAPK) intracellular signaling pathways. 
Three distinct MAPK pathways have been reported. For 
example, in stress-activated MAPK, p38, and c-Jun N termi-
nal kinase have been described as having an important role 
in mediating signals by transcription factors and inflamma-
tory cytokines.73
In a study by Chio et al, experimental rats after TBI 
(Table 1) were randomized to vehicle solution or etanercept 
(5 mg/kg of body weight) intraperitoneally administered 
once every 12 hours for 3 consecutive days.74 Etanercept 
was reported as effective in ameliorating cerebral ischemia 
surrogate markers such as increased cellular levels of gluta-
mate, lactate-to-pyruvate ratio, and increased cellular levels 
of glycerol. Etanercept also ameliorated some brain edema 
and functional (motor and cognitive) signs. TBI-induced 
neuronal damage is mediated by neuronal, glia, and astrocytic 
apoptosis induction expressed by a higher degree of terminal 
deoxynucleotidyl transferase αUTP nick-end labeling and 
neuronal-specific nuclear protein double-positive cells, a 
higher degree of terminal deoxynucleotidyl transferase αUTP 
nick-end labeling and glia fibrillary acidic protein double-
positive cells, and increased numbers of glia fibrillary acidic 
protein positive cells. Other surrogate markers of TBI-induced 
cell damage are MA activation expressed by some markers, 
such as a higher degree of ionized calcium-binding adapter 
molecule 1-positive cells, TNF-α, IL-1β, and IL-6, and all 
these post-TBI inflammatory markers have been reported as 
significantly reduced by treatment with etanercept.
Some experimental evidence underlines that post-TBI 
inflammation may persist longer than the duration of acute 
ischemia. Some studies have reported how MA in the isch-
emic core, the peri-infarct zone, and the contralateral hemi-
sphere may persist for 30 days.75–77 Excess TNF released by 
activated glia may perpetuate inflammation and produce a 
cycle of continued glia activation. Thus, etanercept represents 
a possible anti-inflammatory and neuroprotective therapy 
for TBI (Figure 5).
Monoclonal neutralizing anti-TNF-α antibody adminis-
tered intracerebroventricularly (or into the brain cortex in the 
experimental animals with MCAO significantly decreases 
focal ischemic brain injury. A recent study74 has been con-
ducted to evaluate whether inhibiting the action of TNF-α 
attenuates brain injury and reduces inflammatory responses in 
murine models of ischemic stroke. Mice underwent MCAO 
for 1 hour and monoclonal neutralizing anti-murine TNF-α 
antibody (mAb) was administrated intraventricularly in the 
mouse with temporary MCAO. The authors reported that the 
infarct volume in mice treated with anti-TNF-α mAb was 
significantly smaller than that in the control group.
Selective TNF inhibitors in the 
treatment of brain injury from TBI
Etanercept has been reported as possibly effective in reducing 
TBI-induced cerebral edema, motor and cognitive impair-
ment, and other candidate markers of TBI-linked neuronal 
damage such as upregulation of astrocytes and microglial 
cells, and to modulate other inflammation mediators. It seems 
that etanercept’s effectiveness could be related to the fact that 
this drug is able to reach TBI-lesioned brain tissue and to lower 
TBI-induced cognitive and motor impairment by promoting a 
neurogenesis-involved pathway such as doublecortin (DCX), 
a microtubule-associated protein. DCX is upregulated in neu-
ronal precursors of the developing brain, thus representing a 
candidate target marker of neuronal regeneration achieved by 
blocking TNF-α. DCX expression has been reported as higher 
within areas of the subventricular zone of the lateral ventricles 
and the subgranular zone at the dentate gyrus/hilus interface 
of hippocampus10,11 in the adult brain. In a post-TBI neuronal 
regeneration setting, an increased number of divided cells in 
the subventricular zone and subgranular zone is expressed by 
immature neurons simultaneously with DCX expression. Sev-
eral experimental models suggest that glia TNF-α produces 
neurotoxicity and that TNF-α-linked neurotoxicity may be 
reversible by the blockade of TNF-α.78
Drug Design, Development and Therapy 2014:8submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
12
Tuttolomondo et al
B
lo
ck
in
g 
th
e 
m
ito
ge
n-
ac
tiv
at
ed
 p
ro
te
in
 k
in
as
e
(M
A
P
K
) i
nt
ra
ce
llu
la
r s
ig
na
lin
g 
pa
th
w
ay
s
B
lo
ck
in
g 
of
 Z
n-
m
et
al
lo
pr
ot
ea
se
, T
N
F-
α 
co
nv
er
tin
g
en
zy
m
e 
(T
AC
E)
TN
F 
re
ce
pt
or
 a
nd
 Ig
G
1 
Fc
 fu
si
on
 p
ro
te
in
 a
s 
TN
F-
α 
bl
oc
ke
rs
Fa
ct
or
R
ec
ep
to
r
ty
ro
si
ne
ki
na
se
M
A
P
K
 s
ig
na
lin
g
pa
th
w
ay D
ea
th
re
ce
pt
or
s
TN
FR
1
TN
F
C
ha
ng
es
 in
ge
ne
 e
xp
re
ss
io
n
N
uc
le
us
C
yt
op
la
sm
C N N N
20
 a
a
~8
 a
a
C
yt
op
la
sm
do
m
ai
n
C
ys
-r
ic
h
se
gm
en
t D
is
in
te
gr
in
do
m
ai
n
C
at
al
yt
ic
do
m
ai
n
P
ro
TN
F-
α
tri
m
er
N
ox
1 
m
R
N
A
N
ox
1
R
O
S
D
N
A
C
el
l g
ro
w
th
,
m
or
ph
ol
og
ic
al
 c
ha
ng
e,
tra
ns
fo
rm
at
io
n
TA
C
E
 in
hi
bi
to
r
TA
C
E
TN
FR
2
TN
FR
1
C
N
S
-T
N
Fα
he
te
ro
tri
m
er
s TN
F
K
ey
 fo
r b
io
lo
gi
cT
N
F 
in
hi
bi
to
r
Tr
an
sl
at
io
n
Th
al
id
om
id
e
M
in
oc
yc
lin
e
N
uc
le
us
Tr
an
sc
rip
tio
n
C
el
l
E
ta
ne
rc
ep
t
le
ne
rc
ep
t
Ad
al
im
um
ab
go
lim
um
ab
in
fli
xi
m
ab
TN
F
===
P
P
GR
B
S
O
S
R
as
B
-R
af
?
A
C
B
Fi
gu
re
 4
 T
N
F-
α-
re
la
te
d 
in
fla
m
m
at
io
n 
an
d 
ap
op
to
si
s-
as
so
ci
at
ed
 r
eg
ul
at
or
y 
pa
th
w
ay
s 
as
 p
os
si
bl
e 
th
er
ap
eu
tic
 t
ar
ge
ts
 in
 is
ch
em
ic
 a
nd
 T
BI
-r
el
at
ed
 n
eu
ro
na
l d
am
ag
e 
(A
–C
).
A
bb
re
vi
at
io
ns
: a
a,
 a
m
in
o 
ac
id
s;
 B
-r
af
, r
ap
id
ly
 a
cc
el
er
at
ed
 fi
br
os
ar
co
m
a-
B;
 F
c,
 f
ra
gm
en
t 
cr
ys
ta
lli
za
bl
e 
re
gi
on
; 
C
ys
, c
ys
ta
tin
; 
Ig
G
, i
m
m
un
og
lo
bu
lin
 G
; 
m
R
N
A
, m
es
se
ng
er
 R
N
A
; 
N
O
X
-1
; 
N
A
D
PH
 o
xi
da
se
 1
; 
N
A
D
PH
, n
ic
ot
in
am
id
e 
ad
en
in
e 
di
nu
cl
eo
tid
e 
ph
os
ph
at
e;
 R
O
S,
 r
ea
ct
iv
e 
ox
yg
en
 s
pe
ci
es
; T
Bi
, t
ra
um
at
ic
 b
ra
in
 in
ju
ry
; T
N
F,
 tu
m
or
 n
ec
ro
sis
 fa
ct
or
; T
N
FR
1,
 T
N
F-
α 
re
ce
pt
or
-1
; T
N
F-
α 
co
nv
er
tin
g 
en
zy
m
e;
 T
N
FR
2,
 tu
m
or
 n
ec
ro
sis
 fa
ct
or
 r
ec
ep
to
r 
2.
Drug Design, Development and Therapy 2014:8 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
13
Selective TNF inhibitors in the treatment of brain injury
TN
F-
α
TN
F-
α 
bo
un
d 
to
et
an
er
ce
pt
E
ta
ne
rc
ep
t
R
ed
u
ct
io
n
 o
f 
n
u
m
b
er
s 
o
f
m
ic
ro
g
lia
-T
N
F
-α
 d
o
u
b
le
p
o
si
ti
ve
 c
el
ls
R
ed
u
ct
io
n
 o
f 
n
u
m
b
er
s 
o
f
as
tr
o
cy
te
-T
N
F
-α
  d
o
u
b
le
p
o
si
ti
ve
 c
el
ls
M
o
d
u
la
te
 t
h
e 
ad
ve
rs
e
sy
n
ap
ti
c 
ef
fe
ct
s 
o
f 
ex
ce
ss
T
N
F
R
ed
u
ct
io
n
 o
f 
in
fl
am
m
at
o
ry
 c
yt
o
ki
n
e 
le
ve
ls
P
ro
in
fl
am
m
at
o
ry
 c
yt
o
ki
n
es
: 
st
im
ul
at
e 
th
e 
im
m
un
e 
sy
st
em
Th
1
P
re
sy
na
pt
ic
 n
eu
ro
n
G
lu
ta
m
at
e
De
po
la
riz
at
io
n
D
ep
ol
ar
iz
at
io
n
TN
FR
1 M
A
P
K
C
R
E
B
C
aM
K
 II
P
ro
te
in
 s
yn
th
es
is
P
os
ts
yn
ap
tic
ne
ur
on
A
M
PA
re
ce
pt
or
tra
ffi
ck
in
g
S
yn
ap
tic
 c
le
ft
S
yn
ap
tic
 v
es
ic
le
K
ai
na
te
re
ce
pt
or
A
M
PA
re
ce
pt
or
N
M
D
A
re
ce
pt
or
M
g2
+
re
le
as
e
N
a+
N
a+
N
a+
C
a2
+
C
a2
+
C
a2
+
P
K
C
A
de
ny
l
cy
cl
as
e
C
al
ci
um
 in
flu
x
P
K
A
cA
M
P
C
a2
+
C
a2
+
A
st
ro
cy
te
M
ic
ro
gl
ia
C
a2
+
↑P
S
-1
↑i
N
O
S
↑N
ic
as
tri
n
↑G
FA
P
IL
-1
β
TN
F-
α
IL
-6
IF
N
-γ
TN
F-
α
IL
-2
IL
-6
IL
-1
2
N
uc
le
us
TN
F
TN
F
In
hi
bi
to
rs
 o
f
tra
ns
cr
ip
tio
n
or
 tr
an
sl
at
io
n;
m
od
ul
at
io
n 
of
m
R
N
A
A
nt
i-T
N
F
an
tib
od
y
R
N
A
D
N
A
C
al
m
od
ul
in
Fi
gu
re
 5
 E
ta
ne
rc
ep
t 
ef
fe
ct
iv
en
es
s 
on
 in
fla
m
m
at
or
y 
pa
th
og
en
et
ic
 p
at
hw
ay
s 
of
 n
eu
ro
na
l d
am
ag
e 
af
te
r 
T
BI
 o
r 
is
ch
em
ic
 s
tr
ok
e.
A
bb
re
vi
at
io
ns
: 
A
M
PA
, 
α-
am
in
o-
3-
hy
dr
ox
y-
5-
m
et
hy
l-4
-is
ox
az
ol
ep
ro
pi
on
ic
 a
ci
d;
 C
aM
K
, 
ca
lm
od
ul
in
-r
eg
ul
at
ed
 k
in
as
e;
 c
A
M
P,
 c
yc
lic
 a
de
no
si
ne
-m
on
o-
ph
os
ph
at
e;
 C
R
eB
, 
cA
M
P 
re
sp
on
se
 e
le
m
en
t-
bi
nd
in
g 
pr
ot
ei
n;
 i
FN
, 
in
te
rf
er
on
; 
iL
, 
in
te
rl
eu
ki
n;
 iN
O
S,
 in
du
ci
bl
e 
ni
tr
ic
 o
xi
de
 s
yn
th
as
e;
 M
A
PK
, m
ito
ge
n-
ac
tiv
at
ed
 p
ro
te
in
 k
in
as
e;
 m
R
N
A
, m
es
se
ng
er
 R
N
A
; N
M
D
A
, N
-m
et
hy
l-D
-a
sp
ar
ta
te
; P
K
A
, p
ro
te
in
 k
in
as
e 
A
; P
K
C
, p
ro
te
in
 k
in
as
e 
C
; P
S,
 p
ho
sp
ha
tid
yl
se
ri
ne
 s
yn
th
as
e;
 T
Bi
, 
tr
au
m
at
ic
 b
ra
in
 in
ju
ry
; T
h,
 T
 h
el
pe
r;
 T
N
F,
 t
um
or
 n
ec
ro
si
s 
fa
ct
or
; T
N
FR
1,
 T
N
F-
α 
re
ce
pt
or
-1
.
Drug Design, Development and Therapy 2014:8submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
14
Tuttolomondo et al
Etanercept may improve functional outcomes of TBI 
owing to the fact that it reaches the CSF in rats, thus reach-
ing damaged brain areas. Some authors assessed etanercept’s 
effectiveness on acute neurological and motor injury in rats 
1 day prior to and 7 days after surgery.79 These authors used the 
degree of the co-localizations of 5-bromodeoxyuridine and 
DCX on damaged areas evaluated by immunofluorescence 
staining as markers of brain contusion and brain injury. They 
reported detectable brain levels of etanercept in the damaged 
brain 7 days after systemic administration of etanercept, and 
also reported a lowering action of this drug on neurological 
and motor deficits signs, cerebral contusion markers, and 
degree of expression of brain TNF-α. Furthermore, they 
reported a higher degree of neurogenesis markers such as 
5-bromodeoxyuridine- and DCX-specific markers in the 
contused brain tissues caused by TBI after treatment with 
etanercept, thus showing that etanercept may reach the TBI-
damaged brain tissues, ameliorating outcomes of TBI by a 
broad anti-inflammatory action and a specific promotion of 
neurogenesis.
A study was conducted that aimed to evaluate the role of 
etanercept after TBI on TNF-α-related markers and on astro-
cyte and neuron damage surrogate markers.80 The authors 
used a rat model and, after a mechanical TBI, performed 
a systemic measure of the neurological severity score and 
motor function before injury and at day 3 after etanercept 
administration. They reported a higher degree of microglia-
TNF-α double-positive cells after TBI but not TNF-α neu-
rons or TNF-α astrocyte double-positive cells in the injured 
brain areas. Etanercept administration significantly lowered 
all the surrogate markers of TBI neuronal damage, such as 
numbers of microglia-TNF-α double-positive cells, and 
increased TNF-α levels in the injured brain and ameliorated 
several signs of neurological motor deficits. This study fur-
ther underlined how an early microglia overproduction of 
TNF-α in the injured brain region after TBI could represent 
a main contributor to cerebral ischemia and neurological 
motor deficits, thus representing a candidate therapeutic 
target of etanercept action.
TBI patients do not show clear structural brain defects, 
but in general they frequently suffer from long-lasting cog-
nitive, behavioral, and emotional difficulties. Owing to the 
central role of TNF-α in the regulation of systemic inflam-
matory processes, and in regulating inflammatory-mediated 
neuronal and glia toxicity, it may represent a promising drug 
target even after the early stages of TBI. Some researchers 
reported that TNF-α levels increase after TBI and may also 
be responsible for later secondary damage to brain tissue.80
Wang et al81 evaluated the effects of the activation of the 
p75TNFR signaling pathway in mice with TBI in an experi-
mental model of hybridomas that produced antibodies specific 
for p75TNFR, which is critical to the binding of TNF-α and 
p75TNFR. The authors detected the levels of inflammatory 
factors in C57BL/6 mice with TBI, and then they injected 
the mice with either saline (control) or p75TNFR agonist to 
analyze the effects of p75TNFR agonist mAb on p38MAPK 
and nuclear factor-κB (NF-κB) signals. They showed that 
mAb D8F2 was able to inhibit posttraumatic inflamma-
tory responses effectively, offering an agonist anti-mouse 
p75TNFR mAb which may be used for the clinical treatment 
of inflammation after brain trauma.
Belarbi et al82 conducted a study (Table 1) to evaluate 
the therapeutic potential of a analog of thalidomide, namely 
3,6′-dithiothalidomide (DT), an agent with anti-TNF-α activ-
ity, in a model of chronic neuroinflammation. They showed 
that chronic LPS infusion was characterized by increased 
gene expression of the proinflammatory cytokines TNF-α 
and IL-1β in the hippocampus and that treatment with 
DT normalized TNF-α levels but not IL-1β. The authors 
also showed that treatment with DT ameliorated cognitive 
function in LPS-infused animals, demonstrating that the 
TNF-α synthesis inhibitor DT can significantly reverse 
hippocampus-dependent cognitive impairment induced by 
chronic neuroinflammation.
NF-κB plays important roles in the regulation of apop-
tosis and inflammation. A recent study83 evaluated the effect 
of an NF-κB inhibitor SN50 on cell death and behavioral 
deficits in mice with TBI models. This study showed that 
pretreatment with SN50 significantly lowered TBI-induced 
cell death and motor and cognitive dysfunction and also that 
SN50 lowered TNF-α expression.
Another recent study evaluated the efficacy of the experi-
mental TNF-α synthesis inhibitor DT on neurological deficits 
after a TBI due to a rapid induction of high levels of brain 
TNF-α.84 These authors reported a significant amelioration 
of neurological functional impairment in mice that received 
a one-time administration of DT, thus indicating a possible 
role of DT as a neuroprotective drug against TBI-related 
neuronal damage.
More than a decade after the introduction of biologic 
TNF-α inhibitors into clinical practice, there is substantial 
evidence that excess TNF-α plays a key role in brain dysfunc-
tion and also that physiological levels of TNF-α are involved 
in normal brain physiology.85–87 TNF-α also acts as a glia 
transmitter of glial cell production and has been reported to 
regulate synaptic communication.88,89
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A noninvasive method of delivery of etanercept, through 
perispinal extrathecal administration, was developed for the 
treatment of neuroinflammatory disorders.89 Stroke patients 
and patients with TBI, owing to the reported pathogenic role 
of TNF-α and other cytokines in this clinical context, could 
represent a possible target for these drugs. Furthermore, the 
long interval (years) between the stroke event and rapid clini-
cal improvement that has been described in these patients is 
consistent with experimental evidence that TNF-α generation 
persists in the CSF for very much longer (10 months) than 
in the serum (gone in 6 hours), thus offering a long-term 
opportunity for therapeutic intervention.85
These findings permitted researchers to also evaluate the 
role of etanercept in late stages of post-TBI neuronal dam-
age because the interesting findings on experimental mice 
suggested the possible role of selective TNF-α inhibition in 
ameliorating neuroinflammation-related neuronal damage 
after TBI, also in humans.
Selective TNF inhibitors in the 
treatment of brain injury 
from stroke and from TBI
Since brain injury from stroke and TBI may result in a persis-
tent neuroinflammatory response in the injury penumbra, and 
owing to the fact that this inflammatory response may include 
MA and excess levels of TNF, and that previous experimental 
data suggest etanercept, a selective TNF inhibitor, has the 
ability to ameliorate MA and modulate the adverse synaptic 
effects of excess TNF, it has been hypothesized that perispi-
nal administration may enhance etanercept delivery across 
the blood–CSF barrier.
Perispinal administration of etanercept may facilitate the 
delivery of the drug into the brain. Tobinick et al conducted 
a study to evaluate perispinal etanercept administration 
(Table 1) in patients with chronic ischemic stroke, enrolling 
three consecutive patients with chronic neurological impair-
ment after acute ischemic stroke not resolved after rehabilita-
tion.90 In all these patients treated with etanercept, the authors 
observed a significant clinical improvement that was evident 
within 10 minutes of perispinal injection. They also observed 
a significant amelioration of motor dysfunction, gait disorder, 
hemi-neglect disorders, speech, cognitive dysfunction, and 
behavioral disorders. After a second perispinal etanercept 
dose, they noticed additional clinical improvement.
Furthermore, Tobinick et al conducted another study 
(Table 1) to evaluate the effectiveness of intraspinal etaner-
cept administration in patients with postischemic and post-
TBI neurological impairment, enrolling 629 consecutive 
patients.91 The authors observed a significant improvement 
in motor impairment, spasticity, sensory impairment, cog-
nition, psychological/behavioral function, and aphasia, and 
also an amelioration of pseudobulbar symptoms and urinary 
incontinence. These findings were also observed in patients 
treated even in the late phase of their poststroke neurological 
dysfunction. In this subgroup of patients, the authors also 
observed a significant improvement of motor symptoms and 
spasticity. This study suggested how stroke and TBI may lead 
to delayed neuroinflammatory response in the brain, which 
could be a possible therapeutic target for selective inhibition 
of TNF, even a long time after an acute injury. These find-
ings further permit us to conclude that high brain and serum 
levels of TNF-α may represent a possible pathogenic basis 
of chronic neurological and neuropsychiatric impairment 
after stroke and TBI.
Positron emission tomographic brain imaging and 
pathological examination showed how a chronic neuroin-
flammatory response lasting for years after a single brain 
injury is present in humans and how TNF is fully involved 
in this neuroinflammatory cascade. Very recently, Tobinick 
et al91 reported that a single dose of perispinal etanercept 
produced an amelioration of aphasia, speech apraxia, and left 
hemiparesis in  patients with acute ischemic stroke for more 
than 3 years after acute brain injury. These findings could 
suggest that acute brain-injury-induced pathologic levels of 
TNF may provide a therapeutic target that can be addressed 
years after injury.
Conclusion
Neuronal damage after an ischemic stroke or TBI has a 
complex pathogenesis with several inflammatory pathways 
that have been reported as involved. Several sources of 
evidence indicate that an inflammatory-immunologic cas-
cade is involved in the pathogenesis of cerebral ischemia. 
Circulatory inflammatory cells such as neutrophils and 
macrophages reach the damaged area of the ischemic brain 
in some experimental models of ischemic stroke and also in 
human subjects with cerebral ischemia. Brain resident cells 
such as astrocytes, microglia, or endothelia have also been 
reported to be involved in this immune-inflammatory activa-
tion subsequent to a cerebral injury, either mechanical (TBI) 
or ischemic. These cells, which are involved in this inflam-
matory activation, become able to communicate with one 
another by producing inflammatory mediators such as cytok-
ines and adhesion molecules. These molecules appear to be 
responsible for the accumulation of inflammatory cells in the 
injured brain, and the resulting immunologic-inflammatory 
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cascade produces an environment that may affect the survival 
of neurons subjected to ischemic injury.
Clinical studies have reported a higher degree of proin-
flammatory cytokine and adhesion molecule serum levels 
in the peripheral blood and CSF of patients with ischemic 
stroke. Among the cytokines involved in the pathogenesis 
of ischemic stroke, TNF-α has been reported as higher 
in experimental ischemia at both the mRNA and protein 
levels. Furthermore, increased levels of cytokines, such as 
IL-1β, TNF-α, and IL-6, as well as adhesion molecules, 
such as ICAM-1 have been observed after experimental 
brain ischemia. High IL-6 concentrations in CSF and 
plasma have been associated with larger infarct size, neu-
rological deterioration, and poor outcome, independently 
of the stroke subtype. TNF-α originating from a variety 
of cell types in either the periphery or the brain itself 
can act on the brain to regulate neural–immune interac-
tions as well as other brain functions. TNF-α derived 
from peripheral immune cells can act in a hormone-like 
fashion through the hypothalamus–pituitary–adrenal axis 
and the vagus nerve to stimulate and affect several CNS 
responses.
Several sources of clinical, genetic, and epidemiologic 
evidence indicate a central role of high levels of TNF-α in 
the pathogenesis of ischemic stroke and of TBI, suggesting 
how TNF-α overexpression could be a therapeutic target. 
High levels of TNF-α have been reported as responsible for 
chronic neurologic, neuropsychiatric, and clinical impairment 
in stroke and TBI clinical settings.98,99 On this basis, perispi-
nal administration of etanercept induces significant clinical 
improvement in patients with poststroke and TBI motor, 
sensory, and neuropsychiatric chronic clinical impairment, 
and this extension of the therapeutic time window exists even 
up to 10 years after stroke and TBI.100 Nevertheless, random-
ized clinical trials will be necessary to further quantify and 
characterize the clinical response.
However, ischemic stroke is a heterogeneous disease and 
is not unique, owing to the fact that five subtypes of ischemic 
stroke exist,92,101,102 and some studies report that every subtype 
shows a different degree of immune-inflammatory activation 
in terms of cytokines such as TNF-α in the acute phase.93–95 
On this basis, it is possible to hypothesize differential effec-
tiveness for selective TNF inhibitors in the treatment of brain 
injury from stroke in relation to clinical subtypes of ischemic 
stroke (atherothromboembolic, cardioembolic, or lacunar) 
that express different degrees of immune-inflammatory acti-
vation in the acute phase in terms of cytokine serum levels, 
as reported in some studies.96,97
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